Hydroxycitric Acid (HCA)
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Chemical Class | Hydroxylated tricarboxylic acid (citric acid derivative) |
| Molecular Formula / CAS | C₆H₈O₈ · CAS 6205-14-7 |
| Primary Botanical Source(s) | Garcinia cambogia (Malabar tamarind, kokum), Garcinia indica, Hibiscus sabdariffa |
| Plant Part | Fruit rind |
| Typical Content | The principal organic acid of Garcinia cambogia fruit rind, comprising roughly 10–30% of the dried rind by weight |
| Solubility / Format | Water-soluble organic acid; available as standardised extract powders at multiple potency grades |
| Sourcing Status | Product-live — genuine match via Herbuno’s Garcinia cambogia extract line |
| Buy from Herbuno | HCA 70% Powder (Garcinia Extract) · HCA 60% Powder |
Name origin: Hydroxycitric acid (HCA) is named descriptively for its chemical structure — a hydroxylated derivative of citric acid — and is also known by the synonym garcinia acid, reflecting its principal botanical source. Traditional use: Dried Garcinia cambogia rind, known regionally as kokum or Malabar tamarind, has a long history as a food preservative, souring agent and carminative digestive aid across South and Southeast Asian culinary traditions, used in curries and fish preparations centuries before HCA was identified as its principal organic acid. Research trajectory: Scientific interest in HCA accelerated in the 1960s–70s once researchers identified it as a competitive inhibitor of ATP-citrate lyase, an enzyme central to fatty acid synthesis, launching a substantial line of animal and human research into HCA as a potential weight-management aid; the research trajectory since has been notably mixed, with human clinical trial results ranging from modest positive effects to null findings, making HCA one of the more contested evidence bases in the HerbIQ index. Commercial source: Garcinia cambogia rind is the standard commercial source of HCA, and Herbuno’s standardised extracts reflect this well-established, genuine botanical match.
Evidence for Hydroxycitric Acid (HCA) Applications
Hydroxycitric acid acts as a competitive inhibitor of ATP-citrate lyase, the extramitochondrial enzyme that converts citrate into acetyl-CoA and oxaloacetate — a key step supplying the building blocks for fatty acid and cholesterol synthesis. By limiting acetyl-CoA availability during periods of carbohydrate-driven lipogenesis, HCA is proposed to reduce de novo fat synthesis, which is the mechanistic basis for its use as a weight-management ingredient. Claim strength: Moderate.
A systematic review and meta-analysis of nine randomised controlled trials found a small but statistically significant difference in weight loss favouring HCA over placebo (mean difference: -0.88 kg), while noting that gastrointestinal adverse events were roughly twice as common in the HCA group as in placebo in at least one included trial, and that dosage did not show a clear linear relationship with weight-loss magnitude across the pooled studies (Onakpoya et al. 2011). Claim strength: Moderate.
Not all individual trials support this modest pooled effect. A 12-week randomised, double-blind, placebo-controlled trial in 135 overweight subjects using 1,500 mg/day of HCA found no statistically significant difference in weight loss or fat mass loss between the HCA and placebo groups, concluding that Garcinia cambogia failed to produce weight loss beyond that observed with placebo alone (Heymsfield et al. 1998). This negative trial is frequently cited alongside the positive meta-analysis findings and illustrates genuine inconsistency in the human clinical evidence base. Claim strength: Moderate.
By contrast, a double-blind, randomised, placebo-controlled trial specifically measuring visceral fat accumulation via CT scan over 12 weeks (1,000 mg HCA/day) found a significant reduction in visceral fat area in the HCA group compared to placebo, along with improvements in body indices and lipid laboratory values (Hayamizu et al. 2003). This trial’s use of direct imaging rather than total body weight as the primary outcome represents a methodologically distinct approach from most other HCA trials in this literature. Claim strength: Moderate.
The overall honest summary of the HCA evidence base is one of genuine scientific disagreement rather than a clearly established effect: multiple systematic reviews describe the pooled effect as small and of uncertain clinical significance, individual trial results range from null to modestly positive, and the field continues to call for larger, longer-duration, and more methodologically consistent trials before firm conclusions can be drawn. Formulators should represent this mixed evidence honestly rather than overstating HCA’s weight-management effect. Claim strength: Moderate.
Dosage & Formulator Specification
Human clinical trials have most commonly used HCA doses in the range of 1,000–1,500 mg/day, typically divided across two to three doses taken before meals; the meta-analysis pooling these trials found no clear linear dose-response relationship, meaning higher doses within this range have not consistently produced proportionally greater effects.
Analytical quantification of HCA content is performed by HPLC; because HCA exists in multiple isomeric forms (only the (-)-hydroxycitric acid isomer occurs naturally in Garcinia) and both open and lactone forms, formulators should confirm that a supplier’s HCA percentage refers specifically to the biologically relevant (-)-HCA isomer rather than total organic acid content.
Formulation stability matters for HCA: the compound can convert to its inactive lactone form under certain processing and storage conditions, which is why some commercial HCA extracts are formulated as calcium/potassium salt complexes specifically to improve solubility, bioavailability and stability relative to the free acid form.
Regulatory positioning for HCA follows established Garcinia cambogia food-ingredient precedent in most markets, given its long culinary use history; no HCA-specific regulatory limit exists. Given the genuinely mixed clinical evidence, formulators should avoid overstating weight-loss claims and should represent HCA’s effect size accurately as modest and inconsistently replicated across trials.
Frequently Asked Questions — Hydroxycitric Acid (HCA)
The evidence is genuinely mixed. A meta-analysis of nine randomised trials found a small but statistically significant weight-loss effect compared to placebo, but at least one well-designed individual trial found no significant difference from placebo at all. The overall effect size, where present, is modest.
HCA competitively inhibits ATP-citrate lyase, an enzyme needed to convert citrate into the building blocks used for fatty acid and cholesterol synthesis. By limiting this conversion, HCA is proposed to reduce the body’s conversion of excess carbohydrate into stored fat.
Only the (-)-hydroxycitric acid isomer occurs naturally in Garcinia cambogia and is the biologically relevant form studied in clinical trials. Formulators should confirm that a supplier’s HCA percentage specifically refers to this isomer rather than total organic acid content, which could include less relevant forms.
HCA can convert to an inactive lactone form under certain processing and storage conditions. Some commercial extracts use calcium/potassium salt complexes specifically to improve solubility, bioavailability and shelf stability compared to the free acid form.
Related compounds: Berberine, Corosolic Acid